FindTrial
Sign In

Extending the IASLC Grading System: A Proposal for including Invasive Mucinous Adenocarcinomas of the Lung

Revision of the IASLC Grading System for Invasive Pulmonary Adenocarcinoma: Incorporation of Invasive Mucinous Adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112161
Enrollment
Unknown
Registered
2025-11-11
Start date
2025-11-17
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Observation group:None

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed invasive lung adenocarcinoma; 2. Aged between 18 and 80 years; 3. Available percentage of histological subtypes; 4. Underwent curative surgery without neoadjuvant therapy.

Exclusion criteria

Exclusion criteria: 1. Adenocarcinoma in situ, minimally invasive adenocarcinoma, multifocal adenocarcinoma, and other variant types of adenocarcinoma; 2. Previous history of cancer, synchronous presence of other malignant lung tumors, neoadjuvant radiotherapy or chemotherapy, incomplete resection; 3. Unavailable percentage of histological subtypes, or insufficient pathological evaluation of the entire tumor; 4. Missing information (e.g., clinical/pathological staging, age, sex, and follow-up data).

Design outcomes

Primary

MeasureTime frame
5-year recurrence-free survival rate;—

Secondary

MeasureTime frame
Five-year overall survival rate;Five-year tumor-specific survival rate;—

Countries

China

Contacts

Public ContactHanyue Li

Shanghai Chest Hospital

hanyue_li@hotmail.com+86 131 6227 1361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026